enVVeno Medical Corp Ordinary Shares NVNO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NVNO is a good fit for your portfolio.
News
-
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
-
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
-
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
-
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
-
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
-
enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
-
Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
Trading Information
- Previous Close Price
- $5.05
- Day Range
- $5.05–5.25
- 52-Week Range
- $2.51–6.97
- Bid/Ask
- $5.18 / $5.21
- Market Cap
- $69.16 Mil
- Volume/Avg
- 20,854 / 128,304
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 31
- Website
- https://www.envveno.com
Valuation
|
Metric
|
NVNO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.46 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NVNO
|
|---|---|
Quick Ratio | 33.85 |
Current Ratio | 34.23 |
Interest Coverage | — |
Quick Ratio
NVNO
Profitability
|
Metric
|
NVNO
|
|---|---|
Return on Assets (Normalized) | −53.08% |
Return on Equity (Normalized) | −57.48% |
Return on Invested Capital (Normalized) | −55.49% |
Return on Assets
NVNO
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Rpdtmbpt | Zhbtks | $184.2 Bil | |
SYK
| Stryker Corp | Ltzfbtckp | Hfjq | $125.1 Bil | |
MDT
| Medtronic PLC | Jvndggb | Qrbfwk | $108.5 Bil | |
BSX
| Boston Scientific Corp | Zqwzdrxb | Hqgpbm | $107.1 Bil | |
EW
| Edwards Lifesciences Corp | Yxhpxzhmz | Yfgkwr | $51.4 Bil | |
DXCM
| DexCom Inc | Rhkldmyc | Rzqh | $50.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Xkgrwphrx | Mstj | $25.0 Bil | |
PHG
| Koninklijke Philips NV ADR | Pzjtlzgg | Nwbzpqg | $24.4 Bil | |
ALGN
| Align Technology Inc | Scxrjpjgy | Nhktj | $21.7 Bil | |
PODD
| Insulet Corp | Mdcsbyzsj | Vgxtpw | $12.2 Bil |